www.fdanews.com/articles/63256-crucell-announces-per-c6-commercial-licensing-agreement-with-adimmune-corporation
CRUCELL ANNOUNCES PER.C6 COMMERCIAL LICENSING AGREEMENT WITH ADIMMUNE CORPORATION
October 12, 2006
Dutch biotechnology company Crucell N.V. announced that it has signed a non-exclusive PER.C6 commercial license agreement with the Taiwan-based vaccine company ADImmune Corporation.
BioSpace (http://www.marketwire.com/mw/release_html_pressroom?id=F65B254181F3F030&release_id=171434)